DS 109

Drug Profile

DS 109

Alternative Names: DGLA - second generation; Dihomogammalinolenic-acid - second generation; DS 109A; DS109

Latest Information Update: 17 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dignity Sciences
  • Developer DS Biopharma
  • Class Eicosanoids; Omega-6 fatty acids; Skin disorder therapies; Small molecules; Unsaturated fatty acids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Skin disorders
  • Preclinical Unspecified

Most Recent Events

  • 16 Jan 2017 Preclinical trials in Undefined indication in Ireland (PO) (DS Biopharma pipeline)
  • 06 Jan 2017 DS Biopharma completes a phase I trial in Skin disorders in Ireland
  • 06 Jan 2017 DS Biopharma plans a phase II trial in Rosacea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top